EKSO CFO Wong reports tax-withholding sale of 11,288 shares

Rhea-AI Filing Summary

Ekso Bionics (EKSO) disclosed a Form 4 for CFO Jerome Wong. He sold 11,288 shares of common stock on November 10, 2025 at $4.799 per share to cover tax withholding upon the vesting and settlement of restricted stock awards.

After the transaction, Wong beneficially owns 26,009 shares directly and 2,876 shares indirectly via a 401(k). Share amounts reflect the issuer’s 1‑for‑15 reverse stock split effected on June 2, 2025.

Insider Trade Summary

Net Seller: 11,288 shares ($54,182)

Net Sell 2 txns

Insider Wong Jerome

Role Chief Financial Officer

Sold 11,288 shs ($54K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,288	$4.80	$54K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 26,009 shares (Direct); Common Stock — 2,876 shares (Indirect, By 401(k))

Footnotes (1)

1. Represents shares sold by the Reporting Person on November 10, 2025 to cover tax withholding obligations incurred upon the vesting and settlement of restricted stock awards originally reported by the Reporting Person in Form 4 filed with the Commission on November 7, 2025. These shares were sold in a single transaction at a price of $4.7990 per share. On June 2, 2025, the Issuer effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wong Jerome

(Last) (First) (Middle)

101 GLACIER POINT

SUITE A

(Street)

SAN RAFAEL CA 94901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EKSO BIONICS HOLDINGS, INC. [ EKSO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2025		S		11,288(1)	D	$4.8(2)	26,009(3)	D
Common Stock								2,876(3)	I	By 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person on November 10, 2025 to cover tax withholding obligations incurred upon the vesting and settlement of restricted stock awards originally reported by the Reporting Person in Form 4 filed with the Commission on November 7, 2025.

2. These shares were sold in a single transaction at a price of $4.7990 per share.

3. On June 2, 2025, the Issuer effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

	/s/ Jerome Wong	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did EKSO disclose in this Form 4?

Ekso Bionics reported that its CFO, Jerome Wong, sold 11,288 shares on November 10, 2025 to cover tax withholding tied to vested restricted stock.

At what price were EKSO shares sold by the CFO?

The shares were sold at $4.799 per share in a single transaction.

How many EKSO shares does the CFO own after the sale?

Following the sale, he owns 26,009 shares directly and 2,876 shares indirectly via a 401(k).

What was the reason for the EKSO insider sale?

The sale was made to cover tax withholding obligations from the vesting and settlement of restricted stock awards.

Did EKSO note any stock split affecting share counts?

Yes. Amounts reflect a 1‑for‑15 reverse stock split effected on June 2, 2025.

Who is the reporting person in EKSO’s filing and what is their role?

The reporting person is Jerome Wong, Chief Financial Officer of Ekso Bionics.